Promises of Protein Kinase Inhibitors in Recalcitrant Small-Cell Lung Cancer : Recent Scenario and Future Possibilities
SCLC is refractory to conventional therapies; targeted therapies and immunological checkpoint inhibitor (ICI) molecules have prolonged survival only marginally. In addition, ICIs help only a subgroup of SCLC patients. Different types of kinases play pivotal roles in therapeutics-driven cellular functions. Therefore, there is a significant need to understand the roles of kinases in regulating therapeutic responses, acknowledge the existing knowledge gaps, and discuss future directions for improved therapeutics for recalcitrant SCLC. Here, we extensively review the effect of dysregulated kinases in SCLC. We further discuss the pharmacological inhibitors of kinases used in targeted therapies for recalcitrant SCLC. We also describe the role of kinases in the ICI-mediated activation of antitumor immune responses. Finally, we summarize the clinical trials evaluating the potential of kinase inhibitors and ICIs. This review overviews dysregulated kinases in SCLC and summarizes their potential as targeted therapeutic agents. We also discuss their clinical efficacy in enhancing anticancer responses mediated by ICIs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Cancers - 16(2024), 5 vom: 27. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tiwari, Aniket [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug repurposing |
|---|
| Anmerkungen: |
Date Revised 15.03.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers16050963 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369630394 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369630394 | ||
| 003 | DE-627 | ||
| 005 | 20240315233729.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240313s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers16050963 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM369630394 | ||
| 035 | |a (NLM)38473324 | ||
| 035 | |a (PII)963 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tiwari, Aniket |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Promises of Protein Kinase Inhibitors in Recalcitrant Small-Cell Lung Cancer |b Recent Scenario and Future Possibilities |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a SCLC is refractory to conventional therapies; targeted therapies and immunological checkpoint inhibitor (ICI) molecules have prolonged survival only marginally. In addition, ICIs help only a subgroup of SCLC patients. Different types of kinases play pivotal roles in therapeutics-driven cellular functions. Therefore, there is a significant need to understand the roles of kinases in regulating therapeutic responses, acknowledge the existing knowledge gaps, and discuss future directions for improved therapeutics for recalcitrant SCLC. Here, we extensively review the effect of dysregulated kinases in SCLC. We further discuss the pharmacological inhibitors of kinases used in targeted therapies for recalcitrant SCLC. We also describe the role of kinases in the ICI-mediated activation of antitumor immune responses. Finally, we summarize the clinical trials evaluating the potential of kinase inhibitors and ICIs. This review overviews dysregulated kinases in SCLC and summarizes their potential as targeted therapeutic agents. We also discuss their clinical efficacy in enhancing anticancer responses mediated by ICIs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a drug repurposing | |
| 650 | 4 | |a immune checkpoint inhibitor | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a kinase | |
| 650 | 4 | |a recalcitrant | |
| 650 | 4 | |a small-cell lung cancer | |
| 650 | 4 | |a tumor microenvironment | |
| 700 | 1 | |a Kumari, Beauty |e verfasserin |4 aut | |
| 700 | 1 | |a Nandagopal, Srividhya |e verfasserin |4 aut | |
| 700 | 1 | |a Mishra, Amit |e verfasserin |4 aut | |
| 700 | 1 | |a Shukla, Kamla Kant |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Ashok |e verfasserin |4 aut | |
| 700 | 1 | |a Dutt, Naveen |e verfasserin |4 aut | |
| 700 | 1 | |a Ahirwar, Dinesh Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 16(2024), 5 vom: 27. Feb. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:5 |g day:27 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers16050963 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |e 5 |b 27 |c 02 | ||